^
    1d
    Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer (clinicaltrials.gov)
    P2, N=34, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2026 --> Feb 2027
    Trial completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog)
    |
    KRAS mutation • NRAS mutation • BRAF V600 • BRAF wild-type • RAS wild-type • HRAS mutation • KRAS G12 • NRAS Q61 • KRAS G13 • NRAS G12 • NRAS G13 • KRAS Q61
    |
    Mekinist (trametinib) • omipalisib (GSK2126458)
    2d
    EAY131-S2: Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2) (clinicaltrials.gov)
    P2, N=4, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Jan 2027
    Trial completion date
    |
    GNAQ (G Protein Subunit Alpha Q) • GNA11 (G Protein Subunit Alpha 11)
    |
    Mekinist (trametinib)
    2d
    EAY131-S1: Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1) (clinicaltrials.gov)
    P2, N=50, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    Mekinist (trametinib)
    3d
    Case Report: pembrolizumab monotherapy achieves durable disease control in a patient with BRAF V600E-mutant advanced lung adenocarcinoma and high PD-L1 expression intolerant to BRAF/MEK inhibition. (PubMed, Front Oncol)
    The patient was later hospitalized for "recurrent hemoptysis" and received pemetrexed adjuvant chemotherapy combined with cisplatin...Consequently, a targeted therapy regimen combining low to moderate doses of dabrafenib and trametinib was initiated...Moreover, only one low-grade immune-related adverse event was observed during the course of immunotherapy. Patients with advanced NSCLC and BRAF mutations who cannot tolerate targeted therapy are expected to benefit from immunotherapy.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
    |
    PD-L1 expression • BRAF V600E • PD-L1 overexpression • BRAF V600
    |
    Keytruda (pembrolizumab) • Mekinist (trametinib) • cisplatin • Tafinlar (dabrafenib) • pemetrexed
    5d
    Placing purines in precision medicine: Targeting a metabolic reliance in KRAS-mutant tumors. (PubMed, iScience)
    In KRAS-mutant cancer models, trametinib treatment caused dysregulation of the purine biosynthetic pathway driven by reductions in enzyme GART. This induced vulnerability nominated purine analog 6-thioguanine as a synergistic partner...In vivo, the treatment significantly increases overall survival without systemic toxicity. Integrating drug-induced multi-omic changes with functional screening identifies therapeutic strategies, supporting the use of purine analogs with MEK inhibitors for KRAS-mutant tumors.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    |
    Mekinist (trametinib) • thioguanine
    7d
    SEACRAFT-1: A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations (clinicaltrials.gov)
    P1, N=86, Active, not recruiting, Erasca, Inc. | Trial completion date: Nov 2025 --> Dec 2026
    Trial completion date
    |
    RAS mutation
    |
    Mekinist (trametinib) • naporafenib (ERAS-254)
    7d
    A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2) (clinicaltrials.gov)
    P3, N=78, Active, not recruiting, Erasca, Inc. | Recruiting --> Active, not recruiting | N=470 --> 78
    Enrollment closed • Enrollment change
    |
    NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    NRAS mutation
    |
    Mekinist (trametinib) • temozolomide • dacarbazine • naporafenib (ERAS-254)
    7d
    Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma (clinicaltrials.gov)
    P1, N=27, Completed, H. Lee Moffitt Cancer Center and Research Institute | Active, not recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    Mekinist (trametinib) • Zykadia (ceritinib)
    7d
    DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers. (clinicaltrials.gov)
    P2/3, N=30, Not yet recruiting, Cancer Research UK
    New P2/3 trial
    |
    BRAF V600
    |
    Mekinist (trametinib) • Tafinlar (dabrafenib)
    8d
    Differential Preclinical Efficacy of Combined CDK4/6 and MEK Inhibition in Low-Grade Serous Ovarian Carcinoma Based on KRAS/NF1 Mutational Status. (PubMed, Int J Mol Sci)
    We therefore evaluated cell cycle protein expression by immunohistochemistry (IHC) in 186 LGSOC cases, and evaluated the efficacy of the MEK inhibitor, trametinib, in combination with the CDK4/6 inhibitor, palbociclib, in preclinical models of LGSOC. Acquired drug resistance was linked to increased cyclin D1/E1 expression. This study confirms abnormal p16 IHC as a negative prognostic marker in LGSOC and establishes key determinants of sensitivity to CDK4/6 inhibitor-based therapy.
    Preclinical • Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • NF1 (Neurofibromin 1) • CCND1 (Cyclin D1)
    |
    KRAS mutation • KRAS wild-type
    |
    Mekinist (trametinib) • Ibrance (palbociclib)
    8d
    COMBI-EU: Real-World Evidence on Adverse Event Management and Time on Therapy with Adjuvant Dabrafenib Plus Trametinib in Patients with BRAF V600-Mutant Melanoma. (PubMed, Cancers (Basel))
    High-level TRAE management showed a trend toward improved treatment adherence, which was statistically significant for pyrexia. Optional use of an app did not influence treatment adherence.
    Journal • Adverse events • HEOR • Real-world evidence
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    Mekinist (trametinib) • Tafinlar (dabrafenib)
    10d
    Retrospective Study of Trametinib in Patients With Advanced NF1-Mutant Melanoma. (PubMed, JCO Precis Oncol)
    Despite the small number of patients in our study, our findings suggest the promising activity of trametinib in patients with NF1-mutant melanoma, supporting a rationale for prospective studies of MEK inhibitor therapy.
    Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    NF1 (Neurofibromin 1)
    |
    Mekinist (trametinib)